The most serious complication in the use of coagulation factor concentrates in Hemophilia management is the development of inhibitors. Factor eight inhibitor bypass activity (FEIBA), a coagulation factor concentrate, is used for the treatment of bleeds in inhibitor patients. It is safe and effective in managing inhibitor patients. To further discuss this topic, Takeda and Docplexus have organised a webinar on 29th September 2020, 3:30 pm. Join the experts, Dr. Jerzy Windyga and Dr.
M Joseph John , as they share their insights on the topic- Inhibitor Management With FEIBA. Stay tuned! C-APROM/IN/FEI/0002 Disclaimer: This information is solely intended for the use of Registered Medical Practitioner and Hospital only. This information should not be used or shared or distributed to any other person / party and should be strictly by the intended parties for the intended purposes only. For…
